Telix Confirms Webcast Investor Sessions at Oppenheimer and TD Cowen Conferences
Executives will outline strategy with an update on the regulatory outlook.
Overview
- Managing Director and Group CEO Dr. Christian Behrenbruch will join an Oppenheimer virtual fireside chat on Thursday, February 26, 2026 at 4:40 p.m. EST.
- Dr. Behrenbruch and Kevin Richardson, CEO of Precision Medicine, will present at the TD Cowen conference in Boston on Monday, March 2, 2026 at 1:50 p.m. EST.
- Both sessions will stream live via Telix’s investor relations website, which also provides registration details.
- Telix flags planned U.S. regulatory actions as forward-looking items, including an NDA resubmission for TLX101-Px and a BLA resubmission for TLX250-Px.
- The Melbourne‑headquartered radiopharmaceutical company operates internationally and is dual‑listed on the ASX and Nasdaq.